Evolus (EOLS) Stock Forecast & Price Target

Evolus is viewed favorably because 2Q26 showed durable demand for Jeuveau and emerging traction for Evolysse, with revenue rising 21.2% year over year to $84.1M, a 69.0% adjusted gross margin, and two consecutive quarters of positive adjusted EBITDA. Management also sees a credible path to scale through portfolio expansion, as accounts buying both Jeuveau and Evolysse generate 2.5x greater volume year to date and ~3,500 accounts have already purchased Evolysse, while Sculpt remains on track for FDA approval in 4Q26. With cash and equivalents of $45.2M, FY26 revenue guidance of $330.0M-$337.0M, and a long-term target of sustainable margin expansion, the business appears increasingly capable of leveraging its commercial infrastructure and strengthening profitability.

Evolus is facing a mixed but still fragile operating backdrop, as the U.S. neurotoxin market appears stable while new consumer adoption is soft and existing patients have already stretched treatment intervals, limiting near-term growth. Its outlook is weighed down by a long list of risks, including deteriorating consumer spending, inconsistent commercial execution, competition, pricing pressure, supply chain challenges, potential tariffs, regulatory delays, and higher-than-expected operating expenses. Although the category remains underpenetrated relative to Brazil and Korea, the slower-than-expected ramp of Evolysse and possible negative clinical data updates make the company’s fundamentals look more vulnerable than the headline market stability suggests.